Literature DB >> 34136289

A Rare Twist of the Forgotten Disease: A Case of Fusobacterium necrophorum Sepsis with Portomesenteric Thrombosis and a Review of the Literature.

Nicholas Lazar1, Kamil Sardarli1, Zaid Imam2, Majd Khasawneh3, Ismail Hader4.   

Abstract

Abdominal variants of Lemierre's syndrome presenting with pylephlebitis are rare, and the role of anticoagulation in treatment is controversial. We hereby report a case of pylephlebitis secondary to F. necrophorum bacteremia in a 57-year-old female originating from bacterial translocation secondary to colitis, who developed a favorable outcome with prompt treatment with antibiotics and anticoagulation. We also perform a literature review on similar cases in the literature and discuss management options of this rare but potentially fatal complication.
Copyright © 2021 Nicholas Lazar et al.

Entities:  

Year:  2021        PMID: 34136289      PMCID: PMC8177980          DOI: 10.1155/2021/6699867

Source DB:  PubMed          Journal:  Case Rep Gastrointest Med


  3 in total

1.  Fusobacterium necrophorum Promotes Apoptosis and Inflammatory Cytokine Production Through the Activation of NF-κB and Death Receptor Signaling Pathways.

Authors:  Feng-Feng Wang; Peng-Yu Zhao; Xian-Jing He; Kai Jiang; Tian-Shuo Wang; Jia-Wei Xiao; Dong-Bo Sun; Dong-Hua Guo
Journal:  Front Cell Infect Microbiol       Date:  2022-06-14       Impact factor: 6.073

2.  Pylephlebitis Caused by Fusobacterium nucleatum in a Septuagenarian Healthy Caucasian Male: Atypical Presentation of Lemierre's Syndrome.

Authors:  Muhammad Abbas; Monica Ioana Constantin; Akshay Narendra
Journal:  Case Rep Infect Dis       Date:  2022-01-25

Review 3.  Suppurative Thrombosis of the Portal Vein (Pylephlebits): A Systematic Review of Literature.

Authors:  Dorde Jevtic; Tatjana Gavrancic; Ivana Pantic; Terri Nordin; Charles W Nordstrom; Marina Antic; Nikola Pantic; Marija Kaljevic; Bojan Joksimovic; Milan Jovanovic; Emilia Petcu; Mladen Jecmenica; Tamara Milovanovic; Lawrence Sprecher; Igor Dumic
Journal:  J Clin Med       Date:  2022-08-25       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.